{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:58:43Z","timestamp":1792425523476,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n              <jats:title>Purpose<\/jats:title>\n              <jats:p>Real-world experience with meropenem\/vaborbactam (M\/V) is limited. Our aim is to report a clinical experience of M\/V in the treatment of resistant Gram-negative bacilli.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Methods<\/jats:title>\n              <jats:p>This is a prospective observational study including patients hospitalized in the University Hospital of Pisa (March 2021\u2013Jan 2023) with infections by both extended-spectrum \u03b2-lactamases (ESBL)-producing Enterobacterales and carbapenem-resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> (Kp) treated with M\/V. The primary outcome measure was clinical success, defined as a composite of survival, resolution of signs and symptoms and absence of microbiological failure at day 30 from infection onset. A multivariable regression analysis was performed to identify factors associated with clinical failure. Odds ratio (OR) with 95% confidence intervals (CI) was calculated.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Results<\/jats:title>\n              <jats:p>A total of 104 patients who received M\/V were included: 24\/104 (23.1%) infections were caused by ESBL non-hypervirulent Enterobacterales, 17\/104 (16.3%) by ESBL-producing hypervirulent <jats:italic>Klebsiella pneumoniae<\/jats:italic> (hvKp) and 63\/104 (60.6%) by CRE. The most common infections were bloodstream infections, followed by urinary tract infections, hospital-acquired pneumonia, intra-abdominal infections and others. Septic shock occurred in 16\/104 (15.4%) patients. Clinical success was achieved in 77% of patients, and 30-day mortality rate was 15.4%. In patients with KPC-producing Kp infections, clinical success and 30-day mortality rates were 82% and 11.5%, respectively. On multivariable analysis, SOFA score (OR 1.32, 95% CI 1.02\u20131.7, <jats:italic>p<\/jats:italic>=0.032) was independently associated with clinical failure, while source control (OR 0.16, 95% CI 0.03\u20130.89, <jats:italic>p<\/jats:italic>=0.036) was protective.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Conclusions<\/jats:title>\n              <jats:p>M\/V is a promising therapeutic option against infections caused by difficult-to-treat ESBL-producing Enterobacterales and CR-Kp.<\/jats:p>\n            <\/jats:sec>","DOI":"10.1007\/s10096-024-04758-2","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:02:32Z","timestamp":1708430552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real-world experience with meropenem\/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-4933","authenticated-orcid":false,"given":"Giusy","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Galfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Roberto","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pogliaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesira","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leonildi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-8796","authenticated-orcid":false,"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"4758_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejim.2018.01.029","volume":"53","author":"M Falcone","year":"2018","unstructured":"Falcone M, Tiseo G, Dentali F et al (2018) Predicting resistant etiology in hospitalized patients with blood cultures positive for Gram-negative bacilli. Eur J Intern Med 53:21\u201328. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.029","journal-title":"Eur J Intern Med."},{"key":"4758_CR2","doi-asserted-by":"publisher","first-page":"e0057421","DOI":"10.1128\/AAC.00574-21","volume":"65","author":"A Carattoli","year":"2021","unstructured":"Carattoli A, Arcari G, Bibbolino G et al (2021) Evolutionary trajectories toward ceftazidime-avibactam resistance in Klebsiella pneumoniae clinical isolates. Antimicrob Agents Chemother 65:e0057421. https:\/\/doi.org\/10.1128\/AAC.00574-21","journal-title":"Antimicrob Agents Chemother."},{"key":"4758_CR3","doi-asserted-by":"publisher","first-page":"ofab141","DOI":"10.1093\/ofid\/ofab141","volume":"8","author":"G Tiseo","year":"2021","unstructured":"Tiseo G, Falcone M, Leonildi A et al (2021) Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3. Open Forum Infect Dis 8:ofab141. https:\/\/doi.org\/10.1093\/ofid\/ofab141","journal-title":"Open Forum Infect Dis."},{"key":"4758_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P et al (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28:521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect."},{"key":"4758_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 75:187\u2013212. https:\/\/doi.org\/10.1093\/cid\/ciac268","journal-title":"Clin Infect Dis."},{"key":"4758_CR6","doi-asserted-by":"publisher","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"G Tiseo","year":"2022","unstructured":"Tiseo G, Brigante G, Giacobbe DR et al (2022) Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents 60:106611. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106611","journal-title":"Int J Antimicrob Agents."},{"key":"4758_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 319:788\u2013799. https:\/\/doi.org\/10.1001\/jama.2018.0438","journal-title":"JAMA."},{"key":"4758_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G et al (2018) Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 7:439\u2013455. https:\/\/doi.org\/10.1007\/s40121-018-0214-1","journal-title":"Infect Dis Ther."},{"key":"4758_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciz1131","volume":"71","author":"RK Shields","year":"2020","unstructured":"Shields RK, McCreary EK, Marini RV et al (2020) Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 71:667\u2013671. https:\/\/doi.org\/10.1093\/cid\/ciz1131 Erratum in: Clin Infect Dis. 70:1265","journal-title":"Clin Infect Dis."},{"issue":"7","key":"4758_CR10","doi-asserted-by":"publisher","first-page":"ofaa051","DOI":"10.1093\/ofid\/ofaa051","volume":"19","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, Jorgensen SCJ, Lagnf AM et al (2020) Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious Gram-negative bacterial infections. Open Forum. Infect Dis 19(7):ofaa051. https:\/\/doi.org\/10.1093\/ofid\/ofaa051","journal-title":"Infect Dis."},{"key":"4758_CR11","doi-asserted-by":"publisher","first-page":"ofab371","DOI":"10.1093\/ofid\/ofab371","volume":"8","author":"S Alosaimy","year":"2021","unstructured":"Alosaimy S, Lagnf AM, Morrisette T et al (2021) Real-world, multicenter experience with meropenem-vaborbactam for Gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis 8:ofab371. https:\/\/doi.org\/10.1093\/ofid\/ofab371","journal-title":"Infect Dis."},{"key":"4758_CR12","doi-asserted-by":"publisher","first-page":"dlac022","DOI":"10.1093\/jacamr\/dlac022","volume":"4","author":"M Tumbarello","year":"2022","unstructured":"Tumbarello M, Raffaelli F, Cascio A et al (2022) Compassionate use of meropenem\/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist 4:dlac022. https:\/\/doi.org\/10.1093\/jacamr\/dlac022","journal-title":"JAC Antimicrob Resist."},{"key":"4758_CR13","unstructured":"CDC\/NHSN Surveillance Definitions for Specific Types of Infections. 2023. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/17pscnosinfdef_current.pdf. Accessed on 11 Nov 2023"},{"key":"4758_CR14","unstructured":"CDC\/NHSN bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection). https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/4psc_clabscurrent.pdf. Accessed on 11 Nov 2023"},{"key":"4758_CR15","unstructured":"European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, version 13.0, 02 Jan 2023. EUCAST breakpoints. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.0_Breakpoint_Tables.pdf. Accessed on 5April 2023."},{"key":"4758_CR16","doi-asserted-by":"publisher","first-page":"298.e1","DOI":"10.1016\/j.cmi.2021.06.031","volume":"28","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Galfo V et al (2022) Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). Clin Microbiol Infect 28:298.e1\u2013298.e7. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.031","journal-title":"Clin Microbiol Infect."},{"key":"4758_CR17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/jac\/dkab495","volume":"77","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Arcari G et al (2022) Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21. J Antimicrob Chemother 77:1140\u20131145. https:\/\/doi.org\/10.1093\/jac\/dkab495","journal-title":"J Antimicrob Chemother."},{"key":"4758_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/jac\/dkad206","volume":"78","author":"G Tiseo","year":"2023","unstructured":"Tiseo G, Suardi LR, Leonildi A et al (2023) (2023) Meropenem\/vaborbactam plus aztreonam for the treatment of New Delhi metallo-\u03b2-lactamase-producing Klebsiella pneumoniae infections. J Antimicrob Chemother 78:2377\u20132379","journal-title":"J Antimicrob Chemother."},{"key":"4758_CR19","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/cid\/ciad100","volume":"76","author":"M Falcone","year":"2023","unstructured":"Falcone M, Tiseo G, Carbonara S et al (2023) Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis 76:2059\u20132069. https:\/\/doi.org\/10.1093\/cid\/ciad100","journal-title":"Clin Infect Dis."},{"key":"4758_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","volume":"24","author":"M Falcone","year":"2020","unstructured":"Falcone M, Bassetti M, Tiseo G et al (2020) Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care 24:29. https:\/\/doi.org\/10.1186\/s13054-020-2742-9","journal-title":"Crit Care."},{"key":"4758_CR21","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L et al (2017) Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883\u2013e00817. https:\/\/doi.org\/10.1128\/AAC.00883-17","journal-title":"Antimicrob Agents Chemother."},{"key":"4758_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M et al (2018) Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163\u2013171. https:\/\/doi.org\/10.1093\/cid\/cix783","journal-title":"Clin Infect Dis."},{"key":"4758_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","volume":"76","author":"I Karaiskos","year":"2021","unstructured":"Karaiskos I, Daikos GL, Gkoufa A et al (2021) Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother 76:775\u2013783. https:\/\/doi.org\/10.1093\/jac\/dkaa503","journal-title":"J Antimicrob Chemother."},{"key":"4758_CR24","doi-asserted-by":"publisher","first-page":"106536","DOI":"10.1016\/j.ijantimicag.2022.106536","volume":"59","author":"B Baland\u00edn","year":"2022","unstructured":"Baland\u00edn B, Ballesteros D, Pintado V et al (2022) Multicentre study of ceftazidime\/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents 59:106536. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106536","journal-title":"Int J Antimicrob Agents."},{"key":"4758_CR25","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1128\/AAC.01713-15","volume":"59","author":"E Wenzler","year":"2015","unstructured":"Wenzler E, Gotfried MH, Loutit JS et al (2015) Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother 59:7232\u20137239. https:\/\/doi.org\/10.1128\/AAC.01713-15","journal-title":"Antimicrob Agents Chemother."}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:06:20Z","timestamp":1708430780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":25,"alternative-id":["4758"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04758-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study was approved by local ethical committee (IRB number 61185), and informed consent was obtained from study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"MF received unconditional grants from MSD and grants\/or speaker honoraria from Angelini, Shionogi, Pfizer, Menarini, Gilead and Nordic Pharma. GT received honoraria for educational meetings by Shionogi. Declared conflicts of interest are outside the submitted work and did not affect the scientific objectivity of this study. The other authors have none to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}